Tirzepatide vs Semaglutide for Women Over 40: What the Data Actually Shows

If you’re a woman over 40 reading about GLP-1 medications, you’ve almost certainly run into both names. Tirzepatide (sold under Mounjaro for diabetes and Zepbound for weight loss) and semaglutide (sold under Ozempic for diabetes and Wegovy for weight loss) are the two most-prescribed and most-discussed weight loss compounds of the decade. Both have produced weight loss results that genuinely had not been seen before in any approved medication. Both work, both have real downsides, and they are not interchangeable.

This is a side-by-side of what the published trial data actually shows — specifically pulled apart for women in perimenopause and after — written for someone trying to decide between them, or deciding whether either is right for them.

TL;DR

Short version: Tirzepatide produces more weight loss in the published trials, and head-to-head against semaglutide in type 2 diabetics it was meaningfully better. Semaglutide has the longer real-world safety record and the larger body of long-term outcomes data. For women 40+ navigating perimenopausal weight gain specifically, both have substantial female trial cohorts — but neither was designed around menopause, and that matters.

What these drugs actually are

Both compounds are synthetic peptides modeled on incretin hormones — gut peptides released after eating that signal fullness, slow gastric emptying, and tell the pancreas to release insulin. The body makes its own GLP-1, but it breaks down in minutes. Both semaglutide and tirzepatide are engineered to resist that breakdown and persist in circulation for about a week per dose.

The mechanism difference comes down to which receptors each compound activates:

• Semaglutide binds only to the GLP-1 receptor.
• Tirzepatide binds to both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor.

GIP is the other major incretin hormone, and adding GIP activation to GLP-1 activation appears to produce additive effects on appetite suppression, insulin sensitivity, and adipose tissue function. That’s the mechanistic basis for tirzepatide’s greater weight loss in the trials — and it’s what makes it a different class of drug, not just a more potent version of semaglutide.

For a deeper read on either compound, the tirzepatide profile and semaglutide profile cover the full pharmacology, half-life, references, and women’s-health context for each.

The two pivotal trials, side by side

The reason these numbers exist at all is two enormous Phase III trials.

STEP 1: semaglutide

Published in NEJM in 2021 by Wilding et al. Randomized, double-blind, placebo-controlled. 1,961 participants with obesity or overweight + at least one weight-related condition, but without type 2 diabetes. 68 weeks of treatment with weekly subcutaneous semaglutide at 2.4 mg vs placebo.

• Mean body weight reduction: 14.9% in the semaglutide group vs 2.4% in placebo.
• 86% of participants in the treatment arm lost at least 5% of body weight, 69% lost at least 10%, 50% lost at least 15%.
• The cohort was ~74% female — meaning the headline 14.9% figure is fundamentally a women’s weight loss result with men included, not the other way around.

SURMOUNT-1: tirzepatide

Published in NEJM in 2022 by Jastreboff et al. Randomized, double-blind, placebo-controlled. 2,539 participants with obesity or overweight + at least one weight-related condition, without type 2 diabetes. 72 weeks of treatment with weekly subcutaneous tirzepatide at 5 mg, 10 mg, or 15 mg vs placebo.

• Mean body weight reduction: 15.0% (5 mg), 19.5% (10 mg), and 22.5% (15 mg) — vs 3.1% in placebo.
• At the 15 mg dose, 91% of participants lost at least 5%, 83% lost at least 10%, 57% lost at least 20%, and 36% lost at least 25%.
• The cohort was ~67% female.

The head-to-head: SURPASS-2

Published in NEJM in 2021 by Frias et al. This is the trial that compares the two directly — but in patients with type 2 diabetes, not obesity, so it doesn’t quite settle the weight-loss question on its own. Still: at 40 weeks, tirzepatide at all three doses produced greater A1C reduction and greater weight loss than semaglutide 1.0 mg (the highest available semaglutide diabetes dose at the time). The 15 mg tirzepatide arm lost roughly twice as much weight as the semaglutide arm.

A dedicated head-to-head of tirzepatide vs the weight-loss dose of semaglutide (2.4 mg) — SURMOUNT-5 — read out in 2025, and tirzepatide again produced superior weight loss. So if your decision criterion is “which produces more weight loss,” the published evidence converges on tirzepatide.

Why the female cohort data matters specifically for women 40+

The interesting thing about both trials is that both were majority-female. This is unusual. For decades, weight loss medication trials systematically under-recruited women, and when they did recruit them, postmenopausal women specifically were either underrepresented or analyzed as a subgroup rather than the primary population. STEP 1 and SURMOUNT-1 changed this — not because they were designed around perimenopause, but because women are more likely to seek weight loss treatment, so the trials filled with women.

What this means in practice: the headline numbers — 14.9% and 22.5% — reflect majority-female cohorts, not male-physiology results extrapolated to women. They are, functionally, women’s weight loss numbers.

That said, neither trial broke out perimenopausal vs postmenopausal women as a subgroup analysis. So the question “does this work differently for me specifically at 47 going through perimenopause” is not directly answered by the published data. What we can say with confidence:

• Both compounds produce meaningful weight loss in majority-female cohorts that included women in the 40-65 age range, where most women enter menopause.
• The published subgroup analyses in both trials show similar relative weight loss in older vs younger participants, though absolute weight loss tends to be slightly lower in older cohorts (consistent with what you’d expect from age-related metabolic differences).
• Neither trial enrolled exclusively perimenopausal or postmenopausal women, so any claim that one is “specifically designed for menopause” is marketing, not evidence.

The perimenopausal weight gain question is biologically real. Estrogen withdrawal affects insulin sensitivity, fat distribution (more visceral, less subcutaneous), satiety signaling, and resting metabolic rate. GLP-1 and dual GIP/GLP-1 agonists address parts of this picture directly — particularly the satiety and insulin sensitivity axes — but they are not estrogen replacement, and they do not address the bone density, vasomotor, cognitive, or other estrogen-withdrawal symptoms. If perimenopausal weight gain is your only concern, either of these compounds is supported by trial data. If you have multiple menopause symptoms, GLP-1 agonists address one of them, not all of them.

Side effects: what to actually expect

The side effect profiles are similar. Both compounds slow gastric emptying, and most of the reported side effects come from that.

Common (>10% of trial participants):

• Nausea (about 50% in both trials, mostly in the dose-titration phase)
• Diarrhea (about 20-30%)
• Constipation (about 15-20%)
• Vomiting (about 15-25%)
• Decreased appetite (the intended effect, often reported as a side effect)

Most GI side effects peak during dose escalation (the first 4-12 weeks) and then attenuate. Approximately 4-7% of participants in both trials discontinued treatment due to side effects.

Less common but worth knowing:

• Gallstones: Rapid weight loss of any kind increases gallstone risk. Reported in 1-2.5% of treatment arms in both trials — a real number but a known and manageable risk.
• Pancreatitis: Both labels carry a warning. Background risk in obesity is already elevated; the question of whether GLP-1s further elevate it is still being studied. Stop treatment and seek care for severe abdominal pain.
• Thyroid C-cell tumors: Both labels carry a boxed warning based on rodent studies. Whether this risk translates to humans is unclear; the population studies in humans have not detected an increased incidence, but follow-up is short. Both labels list a personal or family history of medullary thyroid carcinoma or MEN-2 as a contraindication.
• Hypoglycemia: Low in non-diabetic populations because both compounds are glucose-dependent in their insulin effects. Higher if combined with insulin or sulfonylureas in diabetic patients.

There is no published evidence that side effects differ meaningfully between tirzepatide and semaglutide. Anecdotally — and anecdote is not evidence — some patients report greater nausea on tirzepatide at the 15 mg dose. The trial data does not clearly support this; the discontinuation rates were similar.

Cost: brand vs compounded vs telehealth

This is where the real-world picture diverges from the trial picture sharply.

Brand cash prices, monthly (mid-2026):

• Wegovy (semaglutide for weight loss): approximately $1,350
• Zepbound (tirzepatide for weight loss): approximately $1,060
• Ozempic and Mounjaro (the diabetes-indicated versions): similar, but typically not covered for weight loss without a diabetes diagnosis.

Insurance coverage is the deciding factor for most users. Coverage of GLP-1s for weight loss varies dramatically by plan. Many commercial plans now require step therapy (trying lifestyle interventions and other medications first), BMI thresholds (typically ≥30, or ≥27 with comorbidities), and prior authorization. Medicare currently does not cover GLP-1s for weight loss; coverage for diabetes indications is separate.

Compounded versions entered the market during the FDA-declared shortages of brand GLP-1s in 2022-2024. The legal status of compounded semaglutide and tirzepatide has shifted multiple times. As of early 2026, the FDA had resolved the official shortage of tirzepatide and was in the process of phasing out 503A compounding pharmacies’ authority to produce it; semaglutide compounded supply was on a similar timeline. Specific compounding rules are still in flux as of mid-2026, and providers are adjusting in real time — confirm current status with whoever is prescribing. Compounded versions typically cost $300-600 per month rather than $1,000+, which is the main reason patients seek them out, but quality and consistency vary by compounder.

Telehealth providers have become the primary access point for cash-pay GLP-1s. We’re building out a verified directory of women-focused telehealth providers offering these compounds — it’s coming after we finish data verification. Until then, the key thing to ask any provider, telehealth or in-person, is whether they prescribe brand or compounded, what your monthly cost is, and what their protocol is for dose adjustments and side effect management.

Which to choose

Honest framework, not medical advice:

• If you want maximum weight loss based on published trial data, the answer is tirzepatide. Both trials and the head-to-head support this.
• If you want the longest real-world safety track record, the answer is semaglutide. It has been in use as a diabetes treatment since 2017 (versus 2022 for tirzepatide), so the body of post-market safety data is larger.
• If you have type 2 diabetes alongside weight management goals, either compound is appropriate, but tirzepatide has shown superior A1C reduction in head-to-head.
• If cost-via-insurance is the deciding factor, the answer is whichever your plan actually covers. Both are covered by some plans and excluded by others, often in seemingly arbitrary ways.
• If you can’t get insurance coverage and need cash-pay, compounded semaglutide has been more widely available than compounded tirzepatide at lower price points, but this is changing as the FDA tightens compounding rules.

What the trial data doesn’t tell you is which one you will tolerate. Side effect tolerance is highly individual, and many patients try one, struggle with side effects, switch to the other, and tolerate it fine. A reasonable provider will start at the lowest dose, escalate slowly, and switch compounds if you can’t tolerate one.

What to ask a provider before starting

Whether you go through telehealth, a primary care doctor, or an obesity medicine specialist, these are the questions worth asking — they sort the responsible providers from the ones running pill mills:

1. What dose schedule will I be on, and how is escalation paced? Anyone who starts you at a high dose to “speed up results” is not following the trial protocol and is increasing your risk of severe side effects.
2. What’s your protocol for side effect management? A real provider has anti-nausea recommendations, a plan for dose holding, and won’t disappear if you’re vomiting at week three.
3. Are you prescribing brand or compounded? Both are legitimate options under different circumstances. The provider should be able to tell you which they’re prescribing and why.
4. What happens at the end of treatment? Most patients regain a substantial portion of weight when they stop. A provider who hasn’t thought about a maintenance protocol or off-ramp is treating these compounds as a short-term fix when the evidence treats them as long-term medications.
5. Do you take a medical history before prescribing? If the answer is “fill out a form and we’ll send the meds,” that is a red flag. Personal and family thyroid cancer history, pancreatitis history, severe GI conditions, and pregnancy plans all matter.

The bottom line

Tirzepatide and semaglutide are both genuinely effective weight loss medications backed by published Phase III trial data in majority-female cohorts. Tirzepatide produces more weight loss in the published trials and in head-to-head comparisons. Semaglutide has the longer track record and broader real-world use. Neither was designed for perimenopause specifically, but both have substantial data in women in the age range when menopause occurs, and both target metabolic pathways relevant to perimenopausal weight changes.

What neither compound is: an estrogen replacement, a free pass on lifestyle factors, or a guaranteed maintenance solution. The trials measured weight loss while on the medication, not after discontinuation, and the discontinuation studies (notably STEP 4) show substantial regain. These are likely long-term medications for most patients, not 6-month interventions.

Whichever you consider, the deciding factors are realistically: what your insurance covers, what your provider is comfortable prescribing, what your individual side effect tolerance turns out to be, and whether your full clinical picture (other conditions, other medications, menopause symptom profile) actually fits a GLP-1 agonist as the right tool.

References

• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021; 384:989-1002. (STEP 1)
• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022; 387:205-216. (SURMOUNT-1)
• Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. NEJM 2021; 385:503-515. (SURPASS-2)
• Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024; 331:38-48.
• Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022; 24:1553-1564. (STEP 4)

FAQ

Is tirzepatide just a stronger version of semaglutide?

No. It’s a different class of drug. Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 receptor agonist. The addition of GIP activation is a mechanistic difference, not just a potency difference. That’s why the head-to-head trials show greater weight loss with tirzepatide at standard doses, rather than just at higher doses.

Can you take both at the same time?

No published evidence supports combining them, and the side effects (particularly GI) would likely be additive. Reputable providers will not prescribe both simultaneously.

Do they work differently in postmenopausal women than premenopausal women?

The subgroup analyses in both pivotal trials did not break out by menopausal status. Both compounds produced meaningful weight loss in majority-female cohorts in the age range that spans perimenopause and menopause. Whether response differs by menopausal status specifically is not well-characterized in the published data.

Does HRT affect how GLP-1 medications work?

There is no published evidence of significant pharmacokinetic interaction between hormone replacement therapy and either semaglutide or tirzepatide. Both can be taken by women on HRT. Specific clinical questions about your regimen should go to your prescriber.

Can you stop taking it once you’ve reached your goal weight?

You can, but the published data (STEP 4, SURMOUNT-4) shows substantial weight regain after discontinuation, on the order of two-thirds of the lost weight returning within a year. These compounds are most reasonably thought of as long-term medications, similar to how a blood pressure medication is generally not stopped once blood pressure normalizes.

Where can I read more about the compounds individually?

The full research profiles for tirzepatide and semaglutide cover the pharmacology, mechanism, half-life, side effects, references, and women’s-health-specific notes in more depth.